|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | American Soci-ety of Clinical Oncology 2008 clinical practice guideline update:use of chemotherapy and radiation therapy protectants显示文摘 | Hensley ML Hagerty KL Kewalramani T | 2009 | J ClinOncol2009，271，： | 1 |
| 2 | American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants显示文摘 | Hensley ML Hagerty KL Kewalramani T | 2009 | J Clin Oncol2009，27，1： | 1 |
| 3 | Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL显示文摘 | Moskowitz CH Zelenetz AD Kewalramani T | 2005 | Blood2005，106，10： | 1 |
| 4 | Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma显示文摘 | Kewalramani T Zelenetz AD Nimer SD | 2004 | Blood2004，103，10： | 1 |
| 5 | High- dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non- Hodgkin s lymphoma:an intention- to- treat analysis 显示文摘 | Zelenetz AD Hedrick EE | 2000 | Blood2000，96，7： | 1 |
| 6 | American Society of Clinical Oncology 2008 clinical practice guideline update:use of chemotherapy and radiation therapy protectants显示文摘 | Hensley ML Hagerty KL Kewalramani T | | 0，，01： | 1 |
| 7 | American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants显示文摘 | Hensley ML Hagerty KL Kewalramani T | 2009 | J Clin Oncol2009，27，1： | 1 |
| 8 | Rituximab and ICE as second-line therapy before autologous stem cell transp lantation for relapsed or p rimary refractory diffuse large B-cell lymphoma 显示文摘 | KEWALRAMANI T ZELENETZ A D NIMER S D | 2004 | Blood2004，103，10： | 1 |
| 9 | Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relpased or primary refractory diffuse large B-cell lymphoma显示文摘 | HAMLIN P A ZELENETZ A D KEWALRAMANI T | 2003 | Blood2003，102，6： | 1 |
| 10 | Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin disease显示文摘 | Moskowitz CH Kewalramani T Nimer SD | 2004 | Br J Haemato12004，124，5： | 1 |
| 11 | Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma 显示文摘 | ZELENETZ A D HAMLIN P KEWALRAMANI T | 2003 | Ann Oncol2003，14，1： | 1 |
| 12 | Ifosfamide,carboplatin,etoposide(ICE) based second line chemotherapy for the management of relapsed and refractor 5,aggressive non-Hodgkin lymphoma显示文摘 | Zelenetz AD Hamlin P Kewalramani T | 2003 | Ann Oncol2003，14，： | 1 |
| 13 | Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma显示文摘 | Hamlin PA Zelenetz AD Kewalramani T | 2003 | Blood2003，102，6： | 1 |
| 14 | Rituximab and DICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomas显示文摘 | Kewalramani T Zelenetz AD Nimer SD | | 0，，10： | 1 |
| 15 | Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL显示文摘 | Moskowitz CH Zelenetz AD Kewalramani T | 2005 | Blood2005，106，： | 1 |
| 16 | Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive nonHodgkin's lymphoma 显示文摘 | Zelenetz A D Hamlin P Kewalramani T | 2003 | Ann Oncol2003，14，1： | 1 |
| 17 | Autologous transplantation for relapsed or primary refractory peripheral T - cell lymphoma 显示文摘 | KEWALRAMANI T ZELENETZ A D TERUYA FELDSTEIN J | 2006 | Br J Haematol2006，134，2： | 1 |
| 18 | Rituximab and ICEas second-line therapy before autologous stem cell transplantation forrelapsed or primary refractory diffuse large B-cell lymphoma显示文摘 | Kewalramani T Zelenetz AD Nimer SD | 2004 | Blood2004，103，10： | 1 |
| 19 | Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma 显示文摘 | Kewalramani T Zelenetz AD Nimer SD | 2004 | Blood2004，103，10： | 1 |
| 20 | American Society of Clinical Oncology 2008 clinical practice guideline update: use ofchemotherapy and radiation therapy protectants显示文摘 | Hensley ML Hagerty KL Kewalramani T | 2009 | J Clin Oncol2009，27，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员